BIBP’s COVID-19 Vaccine Granted EUA by WHO for the First Time!
On May 7, Tedros Adhanom Ghebreyesus, Director-general of the World Health Organization (WHO), announced that the Inactivated COVID-19 Vaccine (Vero Cell) developed by Beijing Institute of Biological Products Co., Ltd. (BIBP), China National Biotec Group Company Limited (CNBG), Sinopharm (hereinafter referred to as “BIBP’s COVID-19 Vaccine”) was granted the Emergency Use Authorization and included into the Emergency Use Listing (EUL) by the WHO. The certification by the WHO has further proved the safety, efficiency and quality of BIBP’s vaccine.
This is the first Chinese COVID-19 vaccine to be granted the EUL by the WHO, also the first COVID-19 vaccine from non-Western countries approved by the WHO. This is one big leap in the accessibility and affordability of Chinese COVID-19 vaccines as a global public good, especially in developing countries.
This also indicates that the quality, safety, effectiveness and accessibility of BIBP’s COVID-19 vaccine meet the relevant standards and requirements of the WHO, enabling China to contribute more strength to the global fight against the COVID-19 and the building of a community of common health for mankind, to a greater extent and in a broader scope.
Contact us
